On November 1, 2017 BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, reported that it will present data on its Bruton’s Tyrosine Kinase (BTK) inhibitor at the upcoming 59th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting (Press release, BeiGene, NOV 1, 2017, View Source [SID1234521450]). ASH (Free ASH Whitepaper) will take place December 9-12, 2017 in Atlanta, GA.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Oral Presentation, Abstract #152
Title: Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Patients with Indolent and Aggressive Non Hodgkin’s Lymphoma
Presenter: Constantine Tam, MD
Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma – Clinical Studies: Mantle Cell Lymphoma, New Therapies
Date & Time: 12:15pm EST, Saturday, December 9, 2017
Location: Georgia World Congress Center, A411-A412
Poster, Abstract #1745
Title: BGB-3111 in Combination with Obinutuzumab in Patients with Chronic Lymphocytic Leukemia and Follicular Lymphoma
Presenter: Constantine Tam, MD
Session: 642. CLL: Therapy, excluding Transplantation: Poster I
Date & Time: 5:30pm-7:30pm EST, Saturday, December 9, 2017
Location: Georgia World Congress Center, Hall A2
Poster, Abstract #4057
Title: Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Combination with the PD-1 Inhibitor BGB-A317 in Patients with B-Cell Lymphoid Malignancies
Presenter: Gavin Cull, MD
Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma – Clinical Studies: Poster III
Date & Time: 6:00pm-8:00pm EST, Monday, December 11, 2017
Location: Georgia World Congress Center, Hall A2
About BGB-3111
BGB-3111 is a potent and highly selective investigational small molecule inhibitor of BTK. BGB-3111 has demonstrated higher selectivity against BTK than ibrutinib, a BTK inhibitor currently approved by the U.S. Food and Drug Administration and the European Medicines Agency, based on biochemical assays, higher exposure than ibrutinib based on their respective Phase 1 experience in separate studies, and sustained 24-hour BTK occupancy in both the peripheral blood and lymph node compartments.
About BGB-A317
BGB-A317 is an investigational humanized monoclonal antibody that belongs to a class of immuno-oncology agents known as immune checkpoint inhibitors. It is designed to bind to PD-1, a cell surface receptor that plays an important role in downregulating the immune system by preventing the activation of T-cells. BGB-A317 has high affinity and specificity for PD-1. It is differentiated from the currently approved PD-1 antibodies in an engineered Fc region, which is believed to minimize potentially negative interactions with other immune cells. BGB-A317 is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers. BeiGene and Celgene Corporation have a global strategic collaboration for BGB-A317 for solid tumors.